GLG News by Council Members in Member Programs who Treat Fusarium Keratitis

Andrew DahlPresident Ophthalmology Consultants

Medicare is not a free lunch

June 1, 2011

Analysis of:Democrats Say Win in New York U.S. House Race Sends Message on Medicare | www.bloomberg.com

The New York 26th district congressional election results last week are being portrayed as a victory for those opposing the Ryan plan to provide varying (based on income)  amount of dollars to Medicare recipients for them to purchase health insurance under a competitive system within the insurance industry.  This plan would be voluntary for the next ten years, so that anyone 55 or older at present could remain in traditional Medicare for the rest of their lives..

Steve RubinsteinOptometristSound Shore Vision Care

July 2010...B+L Voluntarily Recalls ReNu Multi-Purpose Solution

July 10, 2010

Analysis of:B+L Voluntarily Recalls Certain ReNu Multi-Purpose Solution and ReNu MultiPlus Multi-Purpose Solution in Europe and Middle East | www.visionmonday.com

No this is not 2007! A new problem has occurred in the manufacturing of Baucsh & Lomb's current signature contact lens disinfecting product, ReNu. Bausch has just released BioTrue, the next best product in Contact Lens care about 2 weeks ago.

Darcy RyanOptometristHertzog Eye Associates

Will Ocutec's PEG-based Contact Lens Material Replace Silicone Hydrogel?

July 2, 2010

Analysis of:Ocutec Receives Additional GBP0.5 Million Equity Funding Round | findarticles.com

Ocutec Ltd. announced recently that is has obtained CE Mark approval (Europe's equivalent to the U.S.'s FDA approval) for developing its first poly(ethylene) glycol (PEG) hydrogel-based contact lens product. Testing so far shows that this new contact lens material has similar health benefits and comfort as silicone hydrogels, but can be produced much less expensively. This new class of contact lens material could be the next generation, taking over silicone hydrogel as the material of choice.

Steve RubinsteinOptometristSound Shore Vision Care

Abbott back in contact lens solution game

June 12, 2010

Analysis of:Abbott back in contact lens solution game | www.chicagobreakingbusiness.com

There are new regulations and new contact lens solutions being announced almost weekly. Both Abbott and Bausch & Lomb have released new information on contact lens solutions. The industry leader Alcon's OptiFree with almost 33% of the retail US market should announce a new solution soon.

Steve RubinsteinOptometristSound Shore Vision Care

New Contact Lens Products in the Pipeline From J&J (JNJ)

June 4, 2010

Analysis of:UPDATE 3-J&J sees fast-growing device market | www.reuters.com

At the 2nd qtr reports for Johnson & Johnson Vision (JNJ) products a new announcement for allergy sufferers can lead to a new vehicle for introduction of medications in the eye, and the whole body.

Darcy RyanOptometristHertzog Eye Associates

Releasing Prescriptions Means Losing Some Control Over Patient Care & Revenue

June 1, 2010

Analysis of:Consumers have a right to their prescriptions | www.baltimoresun.com

This is a very touchy subject for a lot of Optometrists/Ophthalmologists, or Eye Care Professionals (ECPs). I think the reason why the topic is sensitive is that when we release spectacle and contact lens prescriptions to our patients, it inherently means we must also release a couple very important things: some control over their care, and some revenue. And though neither of these are things over which we want to lose control, we must adapt to the new rules that govern the way we practice.

Andrew DahlPresident Ophthalmology Consultants

VEGF TRAP shows equal efficacy to Lucentis with longer duration of effect in DME

February 19, 2010

Analysis of:VEGF Trap-Eye Shows Positive Results in Phase II Study in Patients with Diabetic Macular Edema | www.pipelinereview.com

Interim six month data from the DAVINCI clinical trial showed that monthly injections of intravitreal VEGF TRAP in patients with diabetic macular edema produced approximately a 10 letter increase in visual acuity. Patients dosed with 3 initial monthly injections followed as needed injections achieved a similar result. In this latter group, average number of injections in the second three months was 1.4.Injections were well tolerated without serious side effects. The study is continuing

Steve RubinsteinOptometristSound Shore Vision Care

Alcon Expanding Its Drug Offerings and Pipeline with 3 Medications

January 20, 2010

Analysis of:Alcon to purchase rights for two eye care products from Sirion Therapeutics | www.pharmabiz.com

The rights for the the new anti inflammatory medication Durezol is Hot. The rights for Zirgan is a much smaller market, but there is limited competition in that field.The New Dry Eye Syndrome medication for Ocular Surface Disease is the first potential since the blockbuster medication Restasis. This is undergoing clinical clinical testing now. There are one or two other Dry Eye Syndrome medications coming down the pipeline.

Steve RubinsteinOptometristSound Shore Vision Care

Alcon would make a nice prize for Novartis

January 4, 2010

Analysis of:Top News Bloomberg Novartis May Sell Bonds in 2010 for $28.2 Billion Alcon Deal | www.businessweek.com

 It looks like Novartis AG is gearing up to purchase the rest of Alcon, Inc. 

Steve RubinsteinOptometristSound Shore Vision Care

What happens to the "Lifetime" guarantee?

December 21, 2009

Analysis of:TLC Vision, Tiger Woods Sponsor, Files for Bankruptcy | www.bloomberg.com

TLC Vision Corp (TLC),  The Laser Center, marketed their Lifetime touch up at no additional charge. What happens now that they have declared chapter 11 bankruptcy as of 12/21/2009?

Page : 12345678910Next1 to 10 of 140